ArticleScientific reports2016
Tunable switch mediated shikimate biosynthesis in an engineered non-auxotrophic Escherichia coli.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Metabolic engineering ofSynthetic and systems biotechnology · 2027Article
- Biphasic Metabolic Control of Shikimic Acid Production inACS omega · 2026Article
- Construction of a Saccharomyces Cerevisiae Cell Factory for Shikimate Production through Precise Regulatory Strategies.Applied biochemistry and biotechnology · 2026Article
- Synthesis of 4-hydroxybenzoic Acid in Escherichia coli by a Modular co-culture System.Applied biochemistry and biotechnology · 2026Article
- Multiple Metabolic Engineering Strategies to Improve Shikimate Titer inMetabolites · 2023Article
- Engineering a universal and efficient platform for terpenoid synthesis in yeast.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- EngineeredFrontiers in microbiology · 2023Article
- Construction of a switchable synthetic Escherichia coli for aromatic amino acids by a tunable switch.Journal of industrial microbiology & biotechnology · 2020Article
- Programmable biomolecular switches for rewiring flux in Escherichia coli.Nature communications · 2019Article
- Metabolic engineering for the production of l-phenylalanine in3 Biotech · 2019Review
- Cell Factory Design and Culture Process Optimization for Dehydroshikimate Biosynthesis inFrontiers in bioengineering and biotechnology · 2019Article
- Optogenetic regulation of engineered cellular metabolism for microbial chemical production.Nature · 2018Article
- Novel technologies combined with traditional metabolic engineering strategies facilitate the construction of shikimate-producing Escherichia coli.Microbial cell factories · 2017Review
- Improvement of shikimic acid production in Escherichia coli with growth phase-dependent regulation in the biosynthetic pathway from glycerol.World journal of microbiology & biotechnology · 2017Article
- Easy regulation of metabolic flux in Escherichia coli using an endogenous type I-E CRISPR-Cas system.Microbial cell factories · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shikimate is a key intermediate in the synthesis of neuraminidase inhibitors. Compared with traditional methods, microbial production of shikimate has the advantages of environmental friendliness, low cost, feed stock renewability, and product selectivity and diversity. Despite these advantages, shikimate kinase I and II respectively encoded by aroK and aroL are inactivated in most shikimate microbial producers, thus requiring the addition of aromatic compounds during the fermentation process. To overcome this problem, we constructed a non-auxotrophic, shikimate-synthesising strain of Escherichia coli. By inactivation of repressor proteins, blocking of competitive pathways and overexpression of key enzymes, we increased the shikimate production of wild-type E. coli BW25113 to 1.73 g/L. We then designed a tunable switch that can conditionally decrease gene expression and substituted it for the original aroK promoters. Expression of aroK in the resulting P-9 strain was maintained at a high level during the growth phase and then reduced at a suitable time by addition of an optimal concentration of inducer. In 5-L fed-batch fermentation, strain P-9 produced 13.15 g/L shikimate without the addition of any aromatic compounds. The tunable switch developed in this study is an efficient tool for regulating indispensable genes involved in critical metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.